MATCH Biosystems nanotechnology reaches in vitro diagnosis of infections. The new generation of devices from this Valencian startup offers results in less than an hour, with a sensitivity over 90%. see article in: El Español D+I
see article in: El Español D+I
see article in: El Español D+I
see article in: Planta Doce Capital Riesgo
see article in: Planta Doce
CLAVE and BHV Partners invest in MATCH biosystems, a biotechnology company that develops rapid pathogen detection tests in hospital and veterinary clinical settings. The objective of MATCH biosystems is the development of a manageable, low-cost, non-invasive test, capable of accurately detecting the pathogen identified as a clinical target in a few minutes. With current devices, it...
see article in La Vanguardia
see article in Planta Doce
see article in El Referente
see article in Expansion see article in Planta Doce
© BHV Partners, 2022. All rights reserved | Legal disclaimer · Privacy policy · Cookies policy
We use our own and third party cookies to improve your experience and to optimize the operation on the web. If you continue browsing we consider that you accept our cookies policy. More information
La configuració de les galetes d'aquesta web està definida com a "permet galetes" per poder oferir-te una millor experiència de navegació. Si continues utilitzant aquest lloc web sense canviar la configuració de galetes o bé cliques a "Acceptar" entendrem que hi estàs d'acord.
